The FDA will decide later this month whether to approve a novel drug for acute pain that could offer a nonaddictive ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 492.13% and ...

About 422 million people worldwide have diabetes, according to the WHO, and most of them live in low- or middle-income ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Finding an effective supplement that aligns with your fitness goals can be daunting in the world of health and wellness.

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...

The Biden administration proposed expanding coverage of weight loss medication to Medicaid and Medicare recipients. RFK Jr.

Zepbound got FDA approval to treat obesity and weight loss in November 2023, joining Eli Lilly's other tirzepatide-based drug, Mounjaro. The two drugs, along with Novo Nordisk's (NVO) Ozempic and ...

which was approved for weight loss for those with obesity, or who are overweight and have a weight-related health condition, in November 2023.Although the new FDA green light doesn't expand the ...